All In Biotech

Drug Trial Radar · NCT05062889

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment of Stage III and High-risk Stage II Resected Colon Cancer Patients With Adjuvant FOLFOXIRI and/or Post-adjuvant Trifluridine/Tipiracil

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 477 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

477

Planned (sponsor's estimate)

Start

May 17, 2023

Primary completion

Oct 2027

Study completion Dec 2029

Sponsor

Lead sponsor
Gruppo Oncologico del Nord-OvestAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Servier; Foundation Medicine; Seagen Inc.
First posted
Sep 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA after chemotherapy and to evaluate if a further adjuvant treatment with Trifluridine/Tipiracil could increase the rate of cases with undetectable ct-DNA and therefore improve DFS in a population at high-risk of relapse. An additional target-driven cohort of HER2+ RAS wild-type colon cancer patients will be assessed for ct-DNA clearance after a tailored treatment with Trastuzumab and Tucatinib plus FOLFOX

Conditions

  • Stage II Colon Cancer
  • Stage III Colon Cancer
  • HER2-positive Colon Cancer
  • RAS Wild-type Colon Cancer

Interventions

  • 5-Fluorouracil continuous infusion FOLFOXIRI scheduleDrug

    3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.

  • 5-Fluorouracil bolus FOLFOX scheduleDrug

    400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.

  • 5-Fluorouracil continuous infusion FOLFOX scheduleDrug

    2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.

  • Oxaliplatin FOLFOX and FOLFOXIRI scheduleDrug

    85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.

  • Oxaliplatin CAPOX scheduleDrug

    130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.

  • L-LeucovorinDrug

    200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.

  • CapecitabineDrug

    Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.

  • IrinotecanDrug

    165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.

  • Trifluridine/TipiracilDrug

    35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.

  • TrastuzumabDrug

    4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.

  • TucatinibDrug

    300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ct-DNA clearance rate after the end of the adjuvant treatment (ERASE-CRC part 1)Time frame: 6 months from the enrollment of the last patient in the adjuvant treatment
  2. ct-DNA clearance rate after the end of post-adjuvant treatment (ERASE-CRC part 2)Time frame: 6 months from the enrollment of the last patient in post-adjuvant treatment
  3. ct-DNA clearance rate after the end of target-driven adjuvant treatment (ERASE-CRC part 1 target-driven)Time frame: 6 months from the enrollment of the last patient in the target-driven adjuvant treatment

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Ospedale San Donato di Arezzo

    Arezzo, Italy

  • Spedali Civili di Brescia

    Brescia, Italy

  • Fondazione POLIAMBULANZA ISTITUTO OSPEDALIERO

    Brescia, Italy

  • AOU Cagliari PO Policlinico Universitario Duilio Casula Presidio Policlinico Universitario "Duilio Casula"

    Cagliari, Italy

  • A.O.U. di Ferrara Arcispedale Sant'Anna

    Ferrara, Italy

  • A.O.U Careggi

    Florence, Italy

  • E.O. Ospedali Galliera di Genova

    Genova, Italy

  • Ospedale Misericordia di Grosseto

    Grosseto, Italy

  • Azienda USL Toscana Nord Ovest di Livorno

    Livorno, Italy

  • Ospedale San Luca di Lucca

    Lucca, Italy

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

    Meldola, Italy

  • Fondazione IRCCS INT - Milano

    Milan, Italy

  • Ospedale San Raffaele

    Milan, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carita

    Novara, Italy

  • Istituto Oncologico Veneto IOV - IRCCS

    Padua, Italy

  • Azienda USL di Piacenza

    Piacenza, Italy

  • Nuovo Ospedale di Prato

    Prato, Italy

  • AUSL Romagna

    Ravenna, Italy

  • Azienda USL IRCCS di Reggio Emilia (centro principale Reggio Emilia e centro satellite Guastalla).

    Reggio Emilia, Italy

  • Policlinico Tor Vergata Roma

    Roma, Italy

  • Istituto per la ricerca sui tumori Regina Elena

    Roma, Italy

  • Policlinico Fondazione Agostino Gemelli

    Roma, Italy

  • Ospedale Fatebenefratelli Isola Tiberina

    Roma, Italy

  • Ospedale Campostaggia Poggiponsi

    Siena, Italy

  • IRCCS di Candiolo

    Torino, Italy

  • Azienda Sanitaria Universitaria Friuli Centrale

    Udine, Italy

  • Fondazione Casa Sollievo della Sofferenza

    San Giovanni Rotondo, Foggia, Italy

  • Azienda Ospedaliera Cardinale Giovanni Panico

    Tricase, Lecce, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.